AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease: Expert Review

Nonalcoholic fatty liver disease (NAFLD) is a leading etiology for chronic liver disease with immense public health impact, affecting over 25% of the U.S. and global population, of whom up to one in four may have non-alcoholic steatohepatitis (NASH). NASH is associated with significant morbidity and mortality due to complications of liver cirrhosis, hepatic decompensation, and hepatocellular carcinoma (HCC). Recent data confirm that HCC represents the 5th most common cancer and 2nd leading cause of cancer-related death worldwide, and NAFLD has been identified as a rapidly emerging risk factor for this malignancy.

Source link

Related posts

Possible Association of Phlebitis-Induced Colitis With Indigo Naturalis


Why Is A Colonoscopy Recommended?


Pliant Therapeutics raises $62 million for proof-of-concept fibrosis studies


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World